November 3, 2023 – Page 4

Innofactor Plc: Share Repurchase 3.11.2023

Written by Customer Service on November 3, 2023. Posted in Public Companies.

Innofactor Plc Announcement 3.11.2023 Innofactor Plc: Share Repurchase 3.11.2023 In the Helsinki Stock Exchange Trade date 3.11.2023 Bourse trade Buy Share IFA1V Amount 10,000 Shares Average price/ share 1.0900 EUR Total cost 10,900.00 EUR Innofactor Plc now holds a total of 401 889 shares including the shares repurchased on 3.11.2023 On behalf of Innofactor Plc Nordea Bank Oyj Janne Sarvikivi Sami Huttunen Additional information: Sami Ensio, CEO Innofactor Plc Tel. +358 50 584 2029 sami.ensio@innofactor.com www.innofactor.com Attachment Innofactor_3.11_trades

Oma Savings Bank Plc: Acquisition of own shares 3.11.2023

Written by Customer Service on November 3, 2023. Posted in Public Companies.

Oma Savings Bank Plc Stock Exchange Release 3.11.2023 Oma Savings Bank Plc: Acquisition of own shares 3.11.2023 In the NASDAQ OMX Helsinki Trade date 3.11.2023 Bourse trade Buy Share OMASP Amount 6,000 Shares Average price/ share 20.5347 EUR Total cost 123,208.20 EUR Company now holds a total of 183 488 shares including the shares repurchased on 3.11.2023 On behalf of Oma Savings Bank Plc Nordea Bank Finland Plc Janne Sarvikivi Sami Huttunen For further information, please contact: Sarianna Liiri CFO Tel. +358 40 835 6712 sarianna.liiri@omasp.fi Minna Sillanpää CCO Tel. +358 50 66592 minna.sillanpaa@omasp.fi www.omasp.fi ...

Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Written by Customer Service on November 3, 2023. Posted in Mergers And Acquisitions.

Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fund operations into 2026 Funds multiple potentially value-creating milestones, including advancing its lead product candidate in Alpha-1 antitrypsin deficiency (AATD) through a clinical trial Shares to trade on Nasdaq under the ticker “KRRO” commencing on November 6, 2023 CAMBRIDGE, Mass. and LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling treatment of both rare and highly prevalent diseases, today announced the completion of the previously announced business combination between Frequency Therapeutics,...

PodcastOne (Nasdaq: PODC) to Announce Second Quarter Fiscal 2024 Financial Results and Host Investor Webcast on November 9, 2023

Written by Customer Service on November 3, 2023. Posted in Earnings Releases And Operating Results.

– Investor Webcast on Thursday, November 9, 2023 at 1:30 p.m. ET / 10:30 a.m. PT – LOS ANGELES, CA, Nov. 03, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – PodcastOne (Nasdaq: PODC), a leading podcast platform and a subsidiary of LiveOne (Nasdaq: LVO), plans to announce its operating and financial results for its second quarter ended September 30, 2023 on Thursday, November 9, 2023. PodcastOne’s senior management will host a live conference call and audio webcast to provide a business update and discuss its operating and financial results beginning at 1:30 p.m. ET / 10:30 a.m. PT on Thursday, November 9, 2023. Conference Call and Webcast: WHEN: Thursday, November 9th TIME: 1:30 PM ET / 10:30 AM PT DIAL-IN (Toll Free): (888) 350-3870 DIAL IN NUMBER (Local): (646) 960-0308 ACCESS CODE: 3329141 REPLAY NUMBER:...

Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Written by Customer Service on November 3, 2023. Posted in Public Companies.

First-in-human Phase 1 study demonstrates early clinical proof of concept Positive clinical biomarker data demonstrate evidence of immune system activation and the translation of the immunogenic response previously observed in preclinical studies Data represent the first successful administration of intratumoral UNO therapy Additional Phase 1 data for UNO expected in 2024 GARDEN CITY, N.Y. and HAMILTON, Bermuda, Nov. 03, 2023 (GLOBE NEWSWIRE) — Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced encouraging first-in-human and first-in-class clinical data demonstrating a promising safety profile and clear evidence of immune system activation via biomarker response. The single agent treatment in...

Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting

Written by Customer Service on November 3, 2023. Posted in Public Companies.

SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new preclinical data on its drug-Fc conjugate (DFC) candidate, CBO421, at the Society for Immunotherapy of Cancer (SITC)’s 38th Annual Meeting. The conference is taking place November 1-5, 2023, both virtually and in-person in San Diego, CA. “We look forward to sharing data that demonstrate the potential for CBO421 to potently inhibit tumor growth as both a monotherapy and in combination with PD-1 therapies,” said Jeffrey Stein, Ph.D. president and chief executive officer of Cidara. “CD73 plays a significant role in contributing...

Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control

Written by Customer Service on November 3, 2023. Posted in Public Companies.

Intratumoral injection of INTASYL self-delivering RNAi compound targeting CTLA-4 (27790) in combination with systemic anti-PD-1 antibody therapy offers a novel approach to combination Immune Checkpoint Inhibition (ICI) therapies MARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced the presentation of new preclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The event is scheduled to take place in San Diego, California, from November 1-5, 2023. Phio’s innovative preclinical study data highlights the benefit of intratumoral injection (IT) of an INTASYL compound targeting...

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023

Written by Customer Service on November 3, 2023. Posted in Public Companies.

Overall response rate (ORR) of 47% and disease control rate (DCR) of 65% in first line (1L) recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® (pembrolizumab) ORR of 56% in patients with low expression of PD-L1 in the tumor Median overall survival (mOS) of 20.8 months in second line (2L) and beyond patients treated with CUE-101 monotherapy, compared to the historic reported survival of approximately eight months observed in patients treated in 2L in the KEYNOTE-040 trial of pembrolizumab No dose limiting toxicities (DLTs) observed or maximum tolerated dose (MTD) reached to date with CUE-102 at the dose escalation phase CUE-102 demonstrated a 75%-80% DCR at the 4mg/kg and 2mg/kg doses respectively with two patients demonstrating tumor reductions of -30% and -29% BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) —...

Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Written by Customer Service on November 3, 2023. Posted in Public Companies.

MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment MP0317 monotherapy shows a favorable safety profile up to the highest planned doses Patient recruitment of the study’s dose-escalation portion is complete, with final study results expected in H1 2024 Data support continued clinical evaluation of MP0317, including in combination studies ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present additional positive data from its Phase 1 study of MP0317 in patients with advanced solid tumors at the 2023 Annual Meeting of the Society for Immunotherapy...

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Written by Customer Service on November 3, 2023. Posted in Public Companies.

Media Release Statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed and linked to improved clinical outcomes Early increase in absolute lymphocyte count is correlated with the positive Overall Survival results in non-small cell lung cancer patients recently reported at ESMO 2023, and is a potential on-treatment biomarker for clinical benefit Similar immune response biomarkers in the blood were seen in the double-blind, randomized AIPAC Phase IIb trial, which combined efti solely with chemotherapy and did not include any anti-PD-1 therapy SYDNEY, AUSTRALIA, Nov. 03, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing...

Day: November 3, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice